Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
20
ARCT Quote, Financials, Valuation and Earnings
Last price:
$6.80
Seasonality move
:
3.23%
Day range:
$6.23 - $6.61
52-week range:
$5.85 - $24.17
Dividend yield:
0%
P/E ratio:
8.50x
P/S ratio:
2.10x
P/B ratio:
0.83x
Volume:
808.4K
Avg. volume:
1.8M
1-year change:
-63.18%
Market cap:
$187.2M
Revenue:
$138.4M
EPS (TTM):
-$2.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$16M | -$0.80 | -32.55% | -35.32% | $35.50 |
|
CAPR
Capricor Therapeutics, Inc.
|
$480K | -$0.54 | -100% | -240.39% | $20.70 |
|
INO
Inovio Pharmaceuticals, Inc.
|
-- | -$0.48 | -100% | -40.55% | $7.63 |
|
NVAX
Novavax, Inc.
|
$41.6M | -$1.13 | 2.21% | -8.63% | $12.67 |
|
SGMO
Sangamo Therapeutics, Inc.
|
$34.4M | -$0.10 | 433.04% | -32.62% | $3.25 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$6.59 | $35.50 | $187.2M | 8.50x | $0.00 | 0% | 2.10x |
|
CAPR
Capricor Therapeutics, Inc.
|
$29.96 | $20.70 | $1.4B | -- | $0.00 | 0% | 122.18x |
|
INO
Inovio Pharmaceuticals, Inc.
|
$2.02 | $7.63 | $138.8M | -- | $0.00 | 0% | 448.96x |
|
NVAX
Novavax, Inc.
|
$6.84 | $12.67 | $1.1B | 3.87x | $0.00 | 0% | 1.09x |
|
SGMO
Sangamo Therapeutics, Inc.
|
$0.50 | $3.25 | $168M | -- | $0.00 | 0% | 3.77x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$5.27 | $11.75 | $311.4M | -- | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
10.37% | 2.214 | 5.18% | 7.68x |
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | 1.632 | 5.44% | 3.50x |
|
INO
Inovio Pharmaceuticals, Inc.
|
435.62% | 3.119 | 7.99% | 0.74x |
|
NVAX
Novavax, Inc.
|
265.85% | 2.153 | 17.83% | 1.90x |
|
SGMO
Sangamo Therapeutics, Inc.
|
80.29% | 3.451 | 11.72% | 0.62x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings, Inc.
|
$13.4M | -$15.6M | -24.78% | -27.98% | -110.37% | -$19.8M |
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
INO
Inovio Pharmaceuticals, Inc.
|
-$749.7K | -$21.2M | -199.9% | -252.43% | -30140.49% | -$21.6M |
|
NVAX
Novavax, Inc.
|
$50.6M | -$79.4M | -- | -- | -112.72% | $105.8M |
|
SGMO
Sangamo Therapeutics, Inc.
|
-$1.3M | -$36.1M | -242.33% | -587.71% | -6214.29% | -$28.6M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Arcturus Therapeutics Holdings, Inc. vs. Competitors
-
Which has Higher Returns ARCT or CAPR?
Capricor Therapeutics, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -63.94%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.
Company Gross Margin Earnings Per Share Invested Capital ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M -
What do Analysts Say About ARCT or CAPR?
Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.50, signalling upside risk potential of 438.7%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $20.70 which suggests that it could fall by -30.91%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Capricor Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARCTArcturus Therapeutics Holdings, Inc.6 3 0 CAPRCapricor Therapeutics, Inc.8 0 0 -
Is ARCT or CAPR More Risky?
Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, which suggesting that the stock is 110.246% more volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.632%.
-
Which is a Better Dividend Stock ARCT or CAPR?
Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARCT or CAPR?
Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Capricor Therapeutics, Inc. quarterly revenues of --. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.10x versus 122.18x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARCTArcturus Therapeutics Holdings, Inc.2.10x 8.50x $14.2M -$13.4M CAPRCapricor Therapeutics, Inc.122.18x -- -- -$24.6M
-
Which has Higher Returns ARCT or INO?
Inovio Pharmaceuticals, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -30140.49%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.
Company Gross Margin Earnings Per Share Invested Capital ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M -
What do Analysts Say About ARCT or INO?
Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.50, signalling upside risk potential of 438.7%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 277.89%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Inovio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARCTArcturus Therapeutics Holdings, Inc.6 3 0 INOInovio Pharmaceuticals, Inc.2 2 0 -
Is ARCT or INO More Risky?
Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, which suggesting that the stock is 110.246% more volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.544, suggesting its more volatile than the S&P 500 by 54.377%.
-
Which is a Better Dividend Stock ARCT or INO?
Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARCT or INO?
Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.10x versus 448.96x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARCTArcturus Therapeutics Holdings, Inc.2.10x 8.50x $14.2M -$13.4M INOInovio Pharmaceuticals, Inc.448.96x -- -- -$45.5M
-
Which has Higher Returns ARCT or NVAX?
Novavax, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -287.29%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Novavax, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M NVAXNovavax, Inc.71.9% -$1.25 $94.5M -
What do Analysts Say About ARCT or NVAX?
Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.50, signalling upside risk potential of 438.7%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 85.19%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Novavax, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Novavax, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARCTArcturus Therapeutics Holdings, Inc.6 3 0 NVAXNovavax, Inc.5 1 1 -
Is ARCT or NVAX More Risky?
Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, which suggesting that the stock is 110.246% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.
-
Which is a Better Dividend Stock ARCT or NVAX?
Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARCT or NVAX?
Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Novavax, Inc.'s PE ratio is 3.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.10x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARCTArcturus Therapeutics Holdings, Inc.2.10x 8.50x $14.2M -$13.4M NVAXNovavax, Inc.1.09x 3.87x $70.4M -$202.4M
-
Which has Higher Returns ARCT or SGMO?
Sangamo Therapeutics, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -6012.05%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Sangamo Therapeutics, Inc.'s return on equity of -587.71%.
Company Gross Margin Earnings Per Share Invested Capital ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M SGMOSangamo Therapeutics, Inc.-226.68% -$0.11 $31.7M -
What do Analysts Say About ARCT or SGMO?
Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.50, signalling upside risk potential of 438.7%. On the other hand Sangamo Therapeutics, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 550.91%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARCTArcturus Therapeutics Holdings, Inc.6 3 0 SGMOSangamo Therapeutics, Inc.3 3 0 -
Is ARCT or SGMO More Risky?
Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, which suggesting that the stock is 110.246% more volatile than S&P 500. In comparison Sangamo Therapeutics, Inc. has a beta of 1.407, suggesting its more volatile than the S&P 500 by 40.72%.
-
Which is a Better Dividend Stock ARCT or SGMO?
Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Sangamo Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARCT or SGMO?
Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Sangamo Therapeutics, Inc. quarterly revenues of $581K. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Sangamo Therapeutics, Inc.'s net income of -$34.9M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Sangamo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.10x versus 3.77x for Sangamo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARCTArcturus Therapeutics Holdings, Inc.2.10x 8.50x $14.2M -$13.4M SGMOSangamo Therapeutics, Inc.3.77x -- $581K -$34.9M
-
Which has Higher Returns ARCT or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -40.15%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ARCTArcturus Therapeutics Holdings, Inc.94.35% -$0.49 $250.5M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ARCT or VNDA?
Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.50, signalling upside risk potential of 438.7%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARCTArcturus Therapeutics Holdings, Inc.6 3 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ARCT or VNDA More Risky?
Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, which suggesting that the stock is 110.246% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock ARCT or VNDA?
Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARCT or VNDA?
Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.10x versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARCTArcturus Therapeutics Holdings, Inc.2.10x 8.50x $14.2M -$13.4M VNDAVanda Pharmaceuticals, Inc.1.46x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
